NuPotential is pioneering the discovery and development of novel drugs that modulate epigenetic targets and their processes for the treatment of cancer. NuPotential’s proprietary PIER drug discovery platform stems from foundational discoveries linking small molecule epigenetic pathway modulation to cellular reprogramming. Founded in 2007 on the discoveries of Dr. Kenneth Eilersten, Associate Prof., Louisiana State University, when he discovered that modifying a single biochemical pathway could alter key epigenetic modifications in a number of diseases with significant unmet need such as cancer, autoimmune disorders and neurodegenerative diseases.
NuPotential’s lead compounds focus on inhibiting G9a and DNMT1 and their impact on Triple-Negative Breast Cancer (TNBC) and Acute Myeloid Leukemia (AML), respectively.
Epigenetics is the study of changes in gene expression, cellular phenotype or function caused ... READ MORE
NuPotential is developing compounds that inhibit G9a, a key epigenetic target... READ MORE
NuPotential is developing compounds that inhibit DNA methyltransferase 1 (DNMT1)... READ MORE
NuP is working on developing compounds that inhibit two key epigenetic targets...READ MORE